Staurosporine derivatives for use in alveolar rhabdomyosarcoma

Details for Australian Patent Application No. 2006313724 (hide)

Owner Universitat Zurich Novartis Pharma GmbH

Inventors Wachtel, Marco; Schafer, Beat W.; Amstutz, Ralf

Agent Davies Collison Cave

Pub. Number AU-B-2006313724

PCT Pub. Number WO2007/054579

Priority 60/736,222 14.11.05 US

Filing date 13 November 2006

Wipo publication date 18 May 2007

Acceptance publication date 23 December 2010

International Classifications

A61K 31/553 (2006.01) - having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine

A61K 31/4025 (2006.01) - not condensed and containing further heterocyclic rings, e.g. cromakalim

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

29 May 2008 PCT application entered the National Phase

  PCT publication WO2007/054579 Priority application(s): WO2007/054579

23 December 2010 Application Accepted

  Published as AU-B-2006313724

21 April 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006313725-N-sulfamoyl-N'-benzopyranpiperidines as inhbitors of carbonic anhydrases

2006313718-Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and EGFR inhibitors or pyrimidine analogues